Liposomal encapsulated anthracyclines: new therapeutic horizons

Current Oncology Reports

Volumn 3, Issue 2, 2001, Pages 156-162

  Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracycline Antibiotic; Doxil; Doxorubicin; Liposomal Doxorubicin; Proc ASCO

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; DOXORUBICIN; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREAST TUMOR; FEMALE; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; OVARY TUMOR; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DAUNORUBICIN; DOXORUBICIN; FEMALE; HUMANS; LEUKEMIA; LIPOSOMES; LYMPHOMA; MULTIPLE MYELOMA; OVARIAN NEOPLASMS; SARCOMA, KAPOSI;

EID: 0035286282     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0016-5     Document Type: Article

References (51)

1. Di Marco A, Gaetani M, Dorigotti L, et al.: Daunomycin: a new antibiotic of the rhodomycin group. Nature 1964, 201:706. DOI: 10.1038/201706a0
2. Mathe G, Maral R: Second generation anthracyclines. In Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:190–204.
3. Di Marco A, Gaetani M, Scarpinato BM: Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity. Cancer Chemother Rep 1969, 53:33–37.
4. Sandberg JS, Howsden FL, Di Marco A, Goldin A: Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother Rep 1970, 54:1–7.
5. Bonadonna G, Monfardini S, DeLena M, et al.: Phase I and preliminary phase II evaluation of Adriamycin (NSC123127). Cancer Res 1970, 30:2572–2582.
6. Tan C, Tasaka H, Yu KP, et al.: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 1967, 20:333–353. DOI: 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
7. Boiron M, Jacquillat C, Weil M, et al.: Traitement des leucemies aigues granulocytaires par la rubidomycine [in French]. Pathol Biol (Paris) 1967, 15:921–924.
8. Blum R, Carter SK: Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:249–259.
9. Benjamin RS: Adriamycin and other anthracycline antibiotics under study in the United States. In Antitumor Antibiotics (Recent Results in Cancer Research, 60). Edited by Carter SK, Umezawa H, Douros J, Sakurai Y. Berlin: Springer-Verlag,; 1978:230–240.
10. Poste G, Papahadjopoulos D: Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. Proc Natl Acad Sci U S A 1976, 73:1603–1607. DOI: 10.1073/pnas.73.5.1603
11. Rahman A, Goldin A, Schein P: Pharmacologic and therapeutic characteristics of anthracycline liposome preparation. In Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:254–273.
12. Rogers KE, Forssen EA, Tokes ZA: Alternative methods of drug delivery. In Anthracycline Antibiotics in Cancer Therapy (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:282–291.
13. Rahman A, Treat J, Roth JK, et al.: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990, 8:1093–1100.
14. Treat J, Greenspan A, Forst D, et al.: Antitumor activity of liposome encapsulated in doxorubicin in advanced breast cancer: a phase II study. J Natl Cancer Inst 1990, 82:1706–1710. DOI: 10.1093/jnci/82.21.1706
15. Henney JE, Von Hoff DD, Rozencweig M, Muggia FM: Thrombophlebitic potential of intravenous cytotoxic agents. Drug Intell Clin Pharmacol 1977, 11:266–267.
16. Ogawa M, Muggia FM, Rozencweig M: Adriamycin: Its Expanding Role in Cancer Treatment (International Congress Series). Tokyo: Excerpta Medica; 1984.
17. Muggia FM, Green MD, Speyer JL: Cancer Treatment and the Heart. Baltimore: Johns Hopkins University Press; 1992.
18. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993, 19:197–228. DOI: 10.1016/0305-7372(93)90036-Q
19. Rahman A, Fumagalli A, Goodman A, Schein PS: Potential of liposomes to ameliorate anthracyccline-induced cardiotoxicity. Semin Oncol 1984, 11(suppl 3):45–48.
20. Woodle MC, Storm G: Long Circulating Liposomes: Old Drugs, New Therapeutics. Berlin: Springer-Verlag and Landes Bioscience; 1998.
21. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986, 56:6387–6392.
22. Gill PS, Espina BM, Muggia F, et al.: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995, 13:996–1003.
23. Guaglianone P, Chan K, DelaFlor-Weiss E, et al.: Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994, 12:103–110. DOI: 10.1007/BF00874439
24. Gabizon A, Catane R, Uziely B, et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987–992.
25. Cowens JW, Creaven PJ, Greco WR, et al.: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993, 53:2796–2802.
26. Booser D, Esparza-Guerra L, Zou Y, et al.: Liposomal annamycin. Phase I clinical and pharmacological study [abstract]. Proc ASCO 1997, 16:762.
27. Proffit RT, Williams LE, Presant CA, et al.: Tumor imaging potental of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med 1983, 24:45–51.
28. Northfelt DW, Martin FJ, Working P, et al.: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996, 36:55–63.
29. Shapiro CL, Ervin T, Welles L, et al.: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer: TLC D-99 Study Group. J Clin Oncol 1999, 17:1435–1441. A key paper in demonstrating the limitation of dose-intensifying classical liposomes.
30. Krigel RL, Slywotzky CM, Lonberg M, et al.: Treatment of epidemic Kaposi’s sarcoma with a combination of interferonalpha-2b and etoposide. J Biol Respir Modif 1988, 7:359–364.
31. Gill PS, Wernz J, Scadden DT, et al.: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996, 14:2353–2364.
32. Northfelt DW: Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi’s sarcoma. Oncology 1997, 10(suppl 11):21–32.
33. Volm MD, Wernz J: Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy [abstract]. Proc ASCO 1997, 16:46a.
34. Cheung TW, Remick SC, Azarnia N, et al.: AIDS-related Kaposi’s sarcoma: a phase II study of liposomal doxorubicin: the TLC D-99 Study Group. Clin Cancer Res 1999, 5:3432–3437.
35. Valero V, Buzdar AU, Theriault RL, et al.: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999, 17:1425–1434.
36. Ranson MR, Carmichael J, O’Byrne J, et al.: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1996, 15:1385–1391.
37. Lyass O, Uziely B, Ben-Yosef M, et al.: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1027–1047. A key paper linking pharmacology to specific toxicities observed with varied schedules of Doxil. DOI: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
38. Torri V, Harper PG, Colombo N, et al.: Paclitaxel and cisplatin in ovarian cancer [letter]. J Clin Oncol 2000, 18:2349.
39. Delgado G, Potkul RK, Treat JA, et al.: A Phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 1989, 160:812–817.
40. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1996, 15:987–993. This is the original description of the activity of Doxil in ovarian cancer, using a phase II open-label design and standard criteria of response.
41. Gordon AN, Aranai CO, Rose PG, et al.: Phase II study of liposomomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000, 18:3093–3100.
42. Gordon AN, Fleagle JT, Parkin DE, et al.: Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer [abstract]. Proc ASCO 2000, 19:1504.
43. Krishna R, St-Louis M, Mayer LD: Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000, 85:131–141. Report on a potentially important strategy to be utilized in combination with liposomes. DOI: 10.1002/(SICI)1097-0215(20000101)85:1<131::AID-IJC23>3.0.CO;2-R
44. Tulpule A, Rarick MU, Kolitz J, et al.: Liposomal daunorubicin (Daunoxome) is active in the treatment of relapsed/refractory low-grade and intermediate-grade non-Hodgkin’s lymphoma (NHL) [abstract]. Blood 1998, 92(suppl 1):4036.
45. Flinn IW, Goodman SN, Post L, et al.: A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol 2000, 11:691–695. DOI: 10.1023/A:1008361914894
46. Pratt G, Wiles ME, Rawstrom AC, et al.: Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998, 16:47–55. DOI: 10.1002/(SICI)1099-1069(199806)16:2<47::AID-HON622>3.0.CO;2-3
47. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000, 42:40–46. DOI: 10.1016/S0190-9622(00)90007-0
48. Garcia AA, Kempf RA, Rogers M, Muggia FM: A phase II study of doxil (lipsomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 1998, 9:1131–1133. DOI: 10.1023/A:1008439013169
49. Baas P, van Meerbeeck J, Groen H, et al.: Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000, 11:697–700. DOI: 10.1023/A:1008346925273
50. Uziely B, Jeffers S, Isaacson R, et al.: Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies. J Clin Oncol 1995, 13:1777–1785.
51. Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000, 11:1–5. DOI: 10.1023/A:1008365716693